Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (January 2026)
28 slides from Defence Therapeutics Inc Class A's investor presentation, January 2026
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q1 2026 1
Slide 2: Our Vision
Our Vision ● Defence Therapeutics is a publicly traded precision drug-delivery company – focused on unlocking the full potential of cancer biologics. ● Our proprietary Accum® platform enhances intracellular delivery, increasing potency while reducing toxicity in ADCs, radiopharmaceuticals, and other
Slide 3: Potential impact of Accum
Potential impact of Accum The ADC market is booming — but major unmet needs remain. Accum directly solves the #1 failure point in ADCs: payload delivery. High potential – driven by platform leverage: Co-development deals Licensing revenue Acquisition interest Broad, plug-and-play enhancement with en
Slide 4: The issue: ADCs are failing to deliver their potential
19 of 20 ADCs on the market are only second-line The issue: therapies ADCs are High rate of clinical failures ˜40% of ADC trails stopped due to safety failing to concerns ˜40% of patients deliver their do not complete ADC therapy due to toxicities potential On-market and in-development drugs are str
Slide 5: The Promise vs. Reality
5 The Promise vs. Reality ADCs are second line therapies and continue to fail in trials Precise tumor targeting High potency cytotoxic payloads X Limited intracellular payload delivery = Narrow therapeutic window (high doses required, but cause toxicities) Fewer than 5% escape endosomes 5 Investor P
Slide 6: An innovative drug delivery platform
An innovative drug delivery platform Peptide CGYGPKKKRKBGG Cholic acid An engineered “molecular tag” that facilitates intracellular accumulation to improve precision drug delivery Endosome Escape Nuclear Localization ! Protected by 8 granted patents 6 Investor Presentation | Defence Therapeutics
Slide 7: Solving ADC toxicity limitations with a molecular tag
Solving ADC toxicity limitations with a molecular tag Precise tumor targeting High potency cytotoxic payloads + Escapes intracellular defences + Delivers payload to cell nucleus = Expanded therapeutic window (Lower doses needed to achieve effect) 7 Investor Presentation | Defence Therapeutics
Slide 8: Our Value-Inflection Year
Our Value-Inflection Year A Focused, 2026 Strategic Plan Accum® platform programs are well-positioned to achieve value-inflection within 12 months. Our focus is two-fold – enhancing existing, underperforming cancer therapeutics (ADC’s) – while also developing our own (RDC’s) for additional revenue pat
Slide 9: Antibody Drug Conjugates (ADCs)
9 Antibody Drug Conjugates (ADCs) Precision delivery of potent chemotherapy agents Precise tumor targeting High potency cytotoxic drug (payloads) Cell receptor = Next-generation precision oncology drugs 9 9 Investor Presentation | Defence Therapeutics
Slide 10: Increased intracellular accumulation
Increased intracellular accumulation Of Accum-enhanced Kadcyla ! Accum increases intracellular Kadcyla accumulation of ADCs Accum-Kadcyla 10 Investor Presentation | Defence Therapeutics Lacasse V et al., Mol Ther Methods Clin Dev. 2020 Sep 1;19:99-119.
Slide 11: Accum-enhanced potency
Accum-enhanced potency Of Kadcyla (Genentech) in cell models Kadcyla Accum L-Kadcyla Accum M-Kadcyla 50x Accum H-Kadcyla 50x Accum increased the potency of Kadcyla® by 50-fold in vitro 11 Investor Presentation | Defence Therapeutics Lacasse V et al., Mol Ther Methods Clin Dev. 2020 Sep 1;19:99-119.
Slide 12: Accum-enhanced efficacy
Accum-enhanced efficacy Of Kadcyla (Genentech) in vivo models No treatment= tumor 3x within 3w ADC 0.5mg/kg Non-effective dose ADC 3mg/kg ! Non-toxic, sub-effective dose ACCUM-ADC 0.5mg/kg None-toxic, effective dose Accum makes an ineffective dose effective 12 Investor Presentation | Defence Therapeu
Slide 13: Accum improves ADC potency in multiple cancer cell lines
® Accum improves ADC potency in multiple cancer cell lines ADC vs Cell line 1 ADC vs Cell line 2 % Cell survival % Cell survival ADC ADC +Accum® +Accum® Concentration Concentration ! Laboratory data confirms that Accum-enhancement dramatically lowers the amount of drug needed to kill cancer cells 13
Slide 14: Partnership Opportunities
Partnership Opportunities 14 Investor Presentation | Defence Therapeutics
Slide 15: Power of Accum–enhanced ADCs
PARTNERSHIP OPPORTUNITIES Power of Accum–enhanced ADCs Expanding patient access and market opportunities • Increasing the safety and availability of potent precision medicines • Potential to create new patentable products, expand markets and increase revenue for pharma/biotech partners Kadcyla Enher
Slide 16: Recent M&A: ADC-enabling technologies
PARTNERSHIP OPPORTUNITIES Recent M&A: ADC-enabling technologies Oncology ADC market is expected to be $30B by 2033; Technologies that address safety issues are being actively pursued by ADC developers and manufacturers ˜$2.0B synthetic biology / ˜$1.3B non-natural amino-acid platform Multi-target pl
Slide 17: ADCs Partnership and Licensing
PARTNERSHIP OPPORTUNITIES ADCs Partnership Partner to co-develop new • Revive franchises Accum-enhanced ADCs • Second to first line • Rescue late stage and Licensing failed ADCs Pharma/ Biosimilars Biotech ! Two active partnerships secured, plus discussions are underway with multiple prospective glob
Slide 18: Accum validated with novel ADC
PARTNERSHIP OPPORTUNITIES Accum validated with novel ADC Accum may revive ADCs abandoned in ! development, unlocking new markets ADC-X Tumor Volume (mm3) (1 mg/kg) + Accum (1 mg/kg) Days 18 Investor Presentation | Defence Therapeutics
Slide 19: Radiopharmaceuticals can also be enhanced by Accum
PARTNERSHIP OPPORTUNITIES Radiopharmaceuticals can also be enhanced by Accum 2026 Goal:In-house development and Our Active Programs: partnership of RDC’s 1) Accum/AccuTOX - Actinium 225 • 100% owned by Defence Radioactive payload must be near the nucleus to kill the cell • Collaboration with Canadia
Slide 20: Quality controlled Accum supply
PARTNERSHIP OPPORTUNITIES Quality controlled Accum supply for revenue during development and marketing Modelled after Seagen’s dual revenue strategy for licensing and supply ! Establishing in-house quality control to ensure supply and deliver revenue Regulator partner of choice, as a Drug Master Fil
Slide 21: Development & Validation
PARTNERSHIP OPPORTUNITIES Development & Validation Structured approach to validating ACCUM for ADC and RDC performance Structural Integrity Target Binding Biological & DAR Window Integrity Potency GO GO STAGE 1 STAGE 2 STAGE 3 STAGE 4 STAGE 5 STAGE 6 IN VIVO STUDIES NO GO NO GO Physicochemical Formu
Slide 22: Ready. Set. Go!
Ready. Set. Go! Becoming a leading drug delivery platform company ADC partnerships/ licensing Radiopharma asset identified Accum Licensed + 2025-2027 Strategic Plan Accum manufacturing Defence R&D laboratory at Montreal Innovation Park (ADCs & Radiopharma) revenue Therapeutics Launched 2020 2021 2022
Slide 23: 2026: Our value-inflection year
PARTNERSHIP OPPORTUNITIES 2026: Our value-inflection year NEW! USA Bio Scientific Advisory China Bio Partnering Int’l Bio Board Conference Conference Conference World ADC ARC ARC World ADC Conference Publication Dev Conference London Candidate ADC Radio- ACCUM Technology Biotech/ DMF Partner Pharma Ph
Slide 24: Leadership Scientific Team
Leadership Scientific Team Sebastien Plouffe Dr. Maxime Parisotto Chief Scientific Officer, Director Business CEO, Founder & Director Development Financial expert and entrepreneur Ph.D, MBA. Lead Scientist with broad experience in with 30+ years experience with publicly-listed companies research and dr
Slide 25: Scientific Advisory Board
Scientific Advisory Board Rob Leana Danny Chui Brendan Husse ADC & Complex Biologics Antibody & ADC Engineer Scientist & Biotech Manufacturing R&D Scientific Leader Investor Pharmaceutical industry veteran R&D scientific leader with 20+ years in Operator-investor with a background with deep expertise i
Slide 26: The Highlights
The Highlights ● Publicly traded biotech firm based in Montreal, Canada, with an attractive capital structure and long-term investors. ● Worldwide extensive patent portfolio covering the Accum platform technology; 8 granted US patents to date. ● Accum-labelled biologic drugs demonstrate enhanced prec
Slide 27: JOIN US NOW!
JOIN US NOW! CURRENT ASK: Up to $10M USD equity financing; closing Jan 2026 1 R&D Capacity: 2 Business 3 ACCUM Establish Development: Development: rapid-throughput Deliver revenue Manufacturing and assays to assess generating regulatory to enable ACCUM -enhanced partnerships and revenue generating AD
Slide 28: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Defence Therapeutics — Investor Presentation (January 2026) on 6ix